TD Cowen analyst Tyler Van Buren has maintained their bullish stance on OLMA stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tyler Van Buren has given his Buy rating due to a combination of factors that highlight Olema’s differentiated pipeline and upcoming catalysts. He views the initial OP-3136 KAT6 inhibitor data at ASCO as an important proof point, especially if the drug demonstrates a cleaner safety profile than Pfizer’s KAT6i while still showing early antitumor activity in breast, prostate, and lung cancers.
He also emphasizes that the true upside for OP-3136 lies in combination therapy, particularly with Olema’s own endocrine agent palazestrant, where preclinical evidence suggests meaningful synergy that could surpass prior benchmarks. In addition, he is constructive on the Phase III OPERA-01 readout for palazestrant expected in the fall and believes the totality of these data, along with Olema’s positioning in ER+ metastatic breast cancer, supports a favorable risk‑reward and justifies a Buy recommendation.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $38.00 price target.